

# People

## Appointments

### BioStratum appoints new CEO

BioStratum (<http://www.biostratum.com>) has announced the promotion of Robert J. Schotzinger to President and Chief Executive Officer. Schotzinger, who will also serve on BioStratum's Board of Directors, joined BioStratum in November 2000 as Vice President and Chief Medical Officer and was appointed President and Chief Operating Officer in October 2002. Prior to joining BioStratum, Schotzinger held positions of increasing responsibility at Abbott Laboratories.

J. William Freytag, Chairman of BioStratum's Board of Directors, said: 'Since Bob joined BioStratum, we have been impressed with his leadership skills, knowledge of the drug development process and ability to deliver on corporate goals. We are delighted that he has accepted this new appointment and look forward to his continuing success as President and CEO.'

BioStratum is a world leader in basal lamina research and is focused on the discovery and development of novel therapeutic agents for the treatment of diabetes and diabetic complications.

### Perlegen Sciences appoints Mark McCamish to head clinical development

Perlegen Sciences (<http://www.perlegen.com>), a genetics research company that develops therapeutics and diagnostics through its genotyping capabilities, has appointed Mark McCamish as Chief Medical Officer and VP of Clinical Development.

McCamish joins Perlegen from Amgen, where he was the Global Development Leader responsible for the clinical development and successful commercialization of drugs in cardiac, pulmonary and other chronic disease indications. Previously, he was Clinical Studies Management Team Leader, where he was responsible for worldwide clinical research. Prior to joining Amgen, McCamish was with Abbott Laboratories for eight years, where he was directly

involved with launching products in multiple therapeutic areas, including diabetes and obesity. He has also held faculty positions at the University of California at Davis, Michigan State University and Ohio State University.

Brad Margus, CEO of Perlegen, said: 'Mark has broad clinical development expertise in numerous therapeutic areas as well as experience in commercializing discoveries. His leadership role will help to accelerate our application of whole-genome analysis to finding predictive markers for drug response, allowing us to rescue drugs, build a product pipeline and quickly take candidate drugs through clinical development to market.'

### New President and management team at Pyrosequencing

Pyrosequencing (<http://www.pyrosequencing.com>) has announced the appointment of a new management team following the merger with Personal Chemistry. Jeff Bork continues as Chairman of the Board and Chief Executive Officer. Hans Johansson, currently President of Personal Chemistry, becomes the new President and Chief Operating Officer, Mats-Olof Wallin continues as Chief Finance Officer and Marten Winge as Vice President of Marketing. Jon-Sverre Schanche, currently VP of R&D at Personal Chemistry, will be the new VP of R&D and Scott Carr will become President of the merged US subsidiaries.

'The new company, through the merger with Personal Chemistry, will double its turnover and have two independent areas to build its business on, both targeting potentially huge global markets...We are very enthusiastic over the opportunities created by the merger,' commented Hans Johansson.

Pyrosequencing develops, manufactures and sells complete solutions for rapid applied genetic analysis based on its proprietary Pyrosequencing™ technology, a broadly applicable DNA sequencing technique.

### Robert B. Stein named President of Roche Palo Alto

Roche (<http://www.roche.com>) have announced the appointment of Robert B.

Stein as President of Roche Palo Alto. Stein has spent more than 20 years in the pharmaceutical and biotechnology industries at companies including Merck, Ligand and DuPont Pharmaceuticals and has participated in the discovery and development of six marketed medicines. Stein joins Roche from Incyte Corporation where he was President and Chief Scientific Officer.

Jonathan Knowles, Head of Global Research for Roche, said: 'Dr Stein brings to Roche tremendous knowledge in diverse areas of drug discovery. He has extensive experience in disease areas including virology, inflammation and CNS disorders. I expect that Dr Stein will contribute extensively to our drug discovery endeavors, both in his role as the leader of Palo Alto research and as a member of our global research management organization.'

Roche Palo Alto focuses on the discovery and early clinical development of new medicines to treat arthritis, respiratory diseases, CNS disorders and viral diseases.

### TargeGen appoints Mark R. Green to its Scientific Advisory Board

The biopharmaceutical company TargeGen (<http://www.targegen.com>), which focuses on small molecule drugs for the treatment of ischaemic diseases and cancer, has announced the appointment of Mark R. Green to its Scientific Advisory Board.

Green has more than 300 publications to his credit and currently serves as Professor of Medicine and Gilbreth Professor of Clinical Oncology at the Medical University of South Carolina. He is also currently Vice-Chairman of the cancer and leukaemia group B (CALGB), a clinical research group funded by the NCI.

Peter G. Ulrich, President and CEO of TargeGen, said: 'We are honoured to have someone of Dr Green's stature in the field of clinical oncology join our Scientific Advisory Board. TargeGen is rapidly advancing its preclinical oncology program into human clinical trials. Mark's talent and wealth of experience in clinical research in the cancer research field will certainly be of great benefit to us as we approach our first human cancer trials.'

People was written by  
*Chris Watson*